Mental health
Postpartum depression discovery opens door to blood test and earlier treatment
New postpartum depression research could lead to a blood test to identify women at risk and possibly even to a preventive treatment.
The research suggests that pregnant women may have characteristic levels of certain molecules in their blood that can warn that they are at risk of developing postpartum depression (PPD).
These molecules, called neuroactive steroids, are derived from progesterone, a hormone that plays critical roles in pregnancy and menstruation.
Measuring those molecules via a simple blood test could let doctors get women treatment for PPD sooner – possibly even before symptoms appear, the researchers said.
Jennifer Payne, MD is an expert in reproductive psychiatry at UVA Health and the University of Virginia School of Medicine.
She said: “Studying postpartum depression gives us a way to identify biological changes that occur before someone becomes depressed because the timing of postpartum depression is predictable.”
Postpartum depression affects 10 per cent to 15 per cent of new mothers.
While many new mothers suffer mild, temporary “baby blues,” PPD is a long-term condition that can leave moms with persistent sadness, stifling anxiety, a stubborn sense of hopelessness and the feeling that they can’t bond with their baby.
This can take a terrible toll on both mother and child – a toll that can last for years.
Weill Cornell’s Lauren Osborne, MD co-led the study with Payne.
The researcher said: “Postpartum is the only time in people’s lifespans when we know there is a biological trigger which guarantees that a certain percentage of people will become ill.
“If we can untangle this biology and find predictors for it, not only will we be helping women, but it may give us a step up in trying to find predictors for other psychiatric illnesses also.”
It’s unclear why some women develop postpartum depression, but the new findings suggest that an imbalance in the body’s metabolism of progesterone may be a factor.
To better understand the role of progesterone, the researchers focused on the hormone and on its “metabolic pathway” in the body.
The scientists measured levels of neuroactive steroids derived from progesterone in the blood of 136 women during their second and third trimesters.
Of these, 33 went on to develop postpartum depression after giving birth.
Two neuroactive steroids seem to affect the risk of developing PPD – pregnanolone and isoallopregnanolone.
Pregnanolone acts on a particular cellular receptor to reduce stress. Isoallopregnanolone, on the other hand, acts on the same receptor to increase stress.
In the third trimester, women who went on to develop PPD had a lower pregnanolone/progesterone ratio and a higher isoallopregnanolone/pregnanolone ratio compared with those who did not, the researchers found.
Elevated progesterone levels in late pregnancy were also associated with a higher risk of PPD.
The researchers plan to attempt to replicate their results in a larger, more diverse group of women in hopes of developing a clinical test to predict the risk of PPD.
Further, they say their work could lead to a preventive treatment – possibly one of two prescription drugs, brexanolone and zuranolone, already available to treat PPD.
Osborne said: “We don’t know if these drugs would work as a preventive measure for people who are at risk of developing postpartum depression, but based on our findings, they have the potential to prevent [its] development.”
By Somayeh McKian, a member of the clinical advisory board of Vea, the AI-powered mental health journal app
The danger of efficiency culture in women’s mental tech is that we are inadvertently optimizing the very patterns that drive our collective burnout.
When we look at the explosive growth of the femtech sector, the dominant narrative remains focused on speed, tracking, and passive compliance.
We build apps that treat a woman’s emotional state like a broken supply chain or a medical deficit that needs to be optimised, streamlined, or forced into submission.
But true psychological resilience cannot be quantified by a simple mood slider or an algorithmic checkmark.
As a psychotherapist and gender studies scholar, my research into the lived experiences of women, particularly how cultural mandates and bodily surveillance are pathologised, reveals a deep-seated form of suffering.
When women constantly say “yes” while meaning “no,” or ignore a chronically depleted body to maintain a rigid role, they are living out what I call an “inkless life.”
It is a blank manuscript in which their physical and emotional existence has been entirely authored by external critics, medical charts, and the “Discourse of the Other.”
They aren’t suffering from an efficiency problem; they have been stripped of the agency to author their own skin.
If femtech platforms simply digitise these rigid, externalised “shoulds,” they risk becoming high-tech tools of compliance rather than portals of liberation.
The investment community and health tech innovators need to realise that the next frontier of mental health tech isn’t about managing symptoms on the fly; it is about existential archaeology.
We must build digital spaces that serve as a “corporeal pen,” transforming self-reflection from a passive hobby into a defiant, existential act.
True innovation lies in helping women find the meaning, the latent metaphors, and the unique tasks already written into their struggles and transforming inherited pain into a human achievement.
This is exactly the structural paradigm shift we are anchoring at Véa. Instead of building superficial tracking logs, our architecture treats life as a manuscript.
We design clinical narrative journeys that help women decode where their internal boundary scripts were written, recognize how somatic depletion is a truth-teller, and wield phrases like “stop it” not as external policing, but as internal, defiant boundaries.
If we want to build a sustainable ecosystem for women’s health, we must stop funding platforms that merely help women endure their exhaustion more efficiently.
In the intersection of meaningful life and technology, we look at the human spirit not by its current restrictions but by its latent potential for change.
It is time to back technologies that give the fluent soul a sharp new set of instruments to rewrite its own narrative.
Somayeh McKian is a certified psychotherapist, in-training logotherapist, gender studies scholar, published author and part of Véa’s clinical advisory board.
A screen time app that lets friends cut their phone use together has won the £15,000 top prize in a women-led startup competition.
Snitch, led by design engineering MEng graduate Asha Bakhai, took first place at WE Innovate, Imperial College London’s flagship competition for women-led startups.
The team aims to tackle excessive screen use among young people, which some research suggests may have a negative effect on mental and physical health.
The app lets users join accountability groups and set shared limits across their most-used apps.
When one person scrolls, the group’s combined timer counts down. Its founders say this helps build awareness, encourages reflection and supports small changes in behaviour by making screen use a shared responsibility.
Speaking at the WE Innovate Grand Final, Bakhai, co-founder and chief executive of Snitch, said: “Thank you to all the people who have been involved with thinking about what it could look like for young people to not be addicted to their phones.
“Whether that’s our friends who we started this with – exchanging screen time passwords and things like that – or the users along the way who beta tested with us, or our families and our friends who we’ve forced to use our app, even though it failed and bugged out and blocked all their apps. Thank you to all of them – and especially, thank you to WE Innovate for making all of this happen.”
Snitch’s team also includes co-founders Serena Sebastian and Yoshiki Berrecloth.
WE Innovate is a six-month pre-accelerator run by Imperial Enterprise Lab for teams led by female students, recent alumni and early career researchers.
The programme supports 25 women-led teams through masterclasses, business coaching, one-to-one expert support and peer mentoring.
The top five teams competed for a share of a £30,000 prize fund.
Professor Hugh Brady, president of Imperial College London, said: “WE Innovate was born out of the realisation that women founders were grossly underrepresented among our wider founder group across the university – so it was an imperative for Imperial to start such a programme.
“It was just last year that we heard Dame Alison Rose, author of the Rose Review, speak about the untapped economic opportunity and potential of women entrepreneurs in the UK.
“After 12 years, this programme has supported hundreds of women entrepreneurs, leading to exciting ventures across health tech, clean tech and all aspects of deep tech.”
The winning teams were selected by a panel including Kristen McLeod CBE, chief strategy officer at the British Business Bank, and Elizabeth Gooch MBE, founder and former chief executive of EGS plc.
The panel also included Pierre N. Rolin, founder and chief executive of Ankh Impact Ventures, and Professor Mary Ryan, vice-provost for research and enterprise at Imperial.
The final marked the second year of WE Innovate National, a UK-wide programme with separate Grand Final showcases held this month at Queen’s University Belfast, Swansea University and Loughborough University.
Joanna Jensen, founder of skincare brand Childs Farm, gave a keynote address about her experiences as an entrepreneur and co-writing The Rise Report of Female Entrepreneurship.
The report found that the UK economy would be £310bn larger if women started and scaled businesses at the same rate as men.
Jensen said 78 per cent of the founders surveyed reported that human connection had been central to their journey, while one in seven identified loneliness as their biggest challenge as an entrepreneur.
She said: “That is why what Imperial is doing matters so profoundly. Not just here in South Kensington but as WE Innovate goes national.
“Because a founder in Loughborough, Durham or Swansea deserves the same access to networks, mentors, capital and belief as a founder sitting in this room tonight.
“Talent is everywhere. Opportunity, until now, has not been.
“A nationwide network for female founders, being backed by women and men, having doors opened for them by women and men, and then paying that forward: that is how you close a £310 billion gap.
“Not with one programme. With a system of programmes, joined up across the country, and held to account on outcomes.”
Waypoint, led by innovation design engineering MSc student Bana Quronfuleh, received the £7,000 second prize.
The team is developing a video game controller that allows visually impaired players to hear and feel popular games.
AlphaVectors Biotech, led by Imperial alumnus Dr Apanpreet Kaur, received the £5,000 third prize for its lipid nanoparticle platform, which aims to improve the stability of RNA vaccines at room temperature.
Lipid nanoparticles are tiny fat-based particles used to protect and deliver genetic material, including the RNA found in some vaccines.
The other finalists, FluoroCycle and Epile-X, each received £1,500.
PHlora LABS received the Lauren Dennis Award, which was established in memory of a pioneering WE Innovate alumnus, for developing a synbiotic suppository intended to prevent recurrent vaginal infections.
Synbiotics combine beneficial microorganisms called probiotics with substances known as prebiotics, which help them grow.
The award recognises a team demonstrating exceptional entrepreneurial spirit in science, technology, engineering and mathematics and includes a six-month business coaching package.
DisoLens received the Engineers in Business Award, sponsored by the Engineers in Business Fellowship.
The award provides each winner with £1,500 in grant funding, mentorship and a professional CV package for entrepreneurs working across engineering sciences.
The team is developing a self-dissolving biodegradable contact lens intended to remove the need for lenses to be taken out each day.
A £50m maternity consortium will bring together UK clinicians, researchers and communities to tackle the most critical gaps in maternal care.
Funding from the National Institute for Health and Care Research has established the NIHR Inequalities Challenge: Maternity Disparities Consortium under the leadership of the University of Birmingham and Newcastle University.
Higher education bodies, NHS organisations, community groups and voluntary organisations from across the UK will work together through the programme.
The NIHR has committed £50m over five years to support research led by clinicians, researchers and communities across the consortium.
Professor Joht Singh Chandan, consortium co-lead for research at the University of Birmingham, said: “National attention on maternity safety and equity has never been greater, but ambition must now be matched by evidence and implementation.
“Through this consortium, we will work across the UK to understand what works, for whom and in what contexts, and to ensure that research leads to practical changes in care for the women, babies and families who need them most.”
The launch comes at a pivotal moment for UK maternity care, with growing national attention on improving safety, equity and women’s experiences of care.
The government’s renewed Women’s Health Strategy highlights the need to improve care before and between pregnancies for underserved communities.
Against that backdrop, the consortium will generate the evidence, interventions and research capacity needed to help turn national ambition into practical improvements for women, babies and families.
University of Birmingham is leading work to improve maternity care pathways across the antenatal, intrapartum and postnatal periods.
Antenatal care covers pregnancy before labour, while intrapartum care refers to care during labour and birth.
The consortium will examine how women and families can be better supported before pregnancy and between pregnancies.
This includes improving access to advice and care that can help people prepare for pregnancy, manage existing health conditions and reduce risks before they build up.
Other research will focus on improving care during pregnancy, birth and the early weeks after birth.
This will include work on major causes of poor maternal health, such as high blood pressure, diabetes in pregnancy, obesity, perinatal mental health and complications during recovery after birth.
Professor Judith Rankin OBE, consortium co-lead for research and capacity development at Newcastle University, said: “This funding represents a critical opportunity to make the step change we need to improve outcomes for women and their babies.
“Alongside the research, the Consortium will be investing in tomorrow’s research leaders today to ensure we have the capacity to deliver on improving pregnancy outcomes, access to, and experience of, care.”
Cancer2 days agoThousands of women could avoid painful cancer exam with new AI blood test
Insight4 days agoWomen with PMOS should have annual NHS checks, new guidance says
Diagnosis3 days agoTwo “gamechanger” tests set to speed up endometriosis diagnosis on the NHS
Entrepreneur1 week agoKorea’s Femtech Industry Goes Global as Vespexx Hosts Korea Femtech Summit 2026
Fertility2 weeks agoImmunotherapy may temporarily restore fertility in premature menopause
News7 days agoBreast cancer biosensor and low-cost ultrasound startups win women’s health AI competition
News2 weeks agoDon’t miss HTW’s upcoming deep dive into health AI
News7 days agoClue spotlights seven women’s health journeys in new campaign